Exhibit 99.1
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
members of its management team will present at the following investor conferences in May 2019:
Daniel Tassé, Chief Executive Officer, and Kevin
Trapp, Chief Commercial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV, on Tuesday, May 14, 2019, at 11:20am PT.
Kevin Trapp, Chief Commercial Officer, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, May 30, 2019, at
10:30am PT.
A live webcast of the presentation at the Bank of America Merrill Lynch 2019 Health Care Conference will be available on the
Investors & Media section of the Companys website:
https://www.dbv-technologies.com/investor-relations/
. A replay of the presentation will also be available on DBVs website within
one hour after the event.
About DBV Technologies
DBV
Technologies is developing Viaskin
®
, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®,
DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and
non-invasive
product candidates, the Company is dedicated to
safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV
is also pursuing a human
proof-of-concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its
platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part
of the SBF120 index, and the Companys ADSs (each representing
one-half
of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).